Impact of Tamsulosin, Tolterodine and drug-combination on the outcomes of lower urinary tract symptoms secondary to post-ureteroscopy ureteral stent: A prospective randomized controlled clinical study

Abdel-Kader, Osman; Mohyelden, Khaled; Sherif, Mahmoud H.; Aldaqadossi, Hussein; Shelbaya, Ahmed; Khairy, Hosni; El-Nashar, Ahmed

doi:10.1016/j.afju.2016.06.001

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We followed the above search strategy and eventually retrieved 239 articles, 206 of which were excluded by eliminating duplicates and filtering titles and abstracts. Of the remaining 33 articles, 25 were excluded due to either not being found in the literature search or lacking valid data after reading the full articles, and eight studies were ultimately included to evaluate the efficacy and safety of tolterodine and α-adrenergic receptor blockers for the treatment of ureteral stent-related symptoms [8,[13][14][15][16][17][18][19]. The details, characteristics, and baseline summaries of the included studies are shown in Table 1.…”

Section: Study Selection Search Results and Characteristics Of The Tr...mentioning

confidence: 99%

Comparison of the efficacy and complications of tolterodine and α-adrenergic receptor blockers in improving ureteral stent-related symptoms: A systematic review and meta-analysis

Liu,

Mao

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Objective We conducted a systematic evaluation of the therapeutic efficacy and complications of tolterodine and α-adrenergic receptor blockers in alleviating ureteral stent-related symptoms. Methods Until August 2023, we conducted a comprehensive literature search on PubMed, Embase, Web of Science, and Cochrane Library to identify randomized controlled trials evaluating the efficacy and complications of tolterodine and α-adrenergic receptor blockers in treating ureteral stent-related symptoms. Two reviewers independently screened studies and extracted data. The scores from various domains of the Ureteral Stent Symptom Questionnaire (USSQ) were summarized and compared, and statistical analysis was performed using RevMan 5.4.0 software. Results A total of 8 studies met the inclusion criteria for our analysis. These studies were conducted at different centers. All studies were randomized controlled trials, involving a total of 487 patients, with 244 patients receiving α-adrenergic receptor blockers and 243 patients receiving tolterodine. The results showed that tolterodine demonstrated significantly better improvement in body pain (MD, 1.56; 95% CI [0.46, 2.66]; p = 0.005) (MD, 0.46; 95% CI [0.12, 0.80]; p = 0.008) (MD, 3.21; 95% CI [1.89, 4.52]; p = 0.00001) among patients after ureteral stent placement compared to α-adrenergic receptor blockers at different time points. Additionally, at 4 weeks, tolterodine showed superior improvement in general health (MD, 0.15; 95% CI [0.03, 0.27]; p = 0.01) and urinary symptoms (MD, 1.62; 95% CI [0.59, 2.66]; p = 0.002) compared to α-adrenergic receptor blockers, while at 6 weeks, tolterodine showed better improvement in work performance (MD, -1.60; 95% CI [-2.73, -0.48]; p = 0.005) compared to α-adrenergic receptor blockers. Additionally, the incidence of dry mouth (RR, 4.21; 95% CI [1.38, 12.87]; p = 0.01) is higher with the use of tolterodine compared to α-adrenergic receptor blockers. However, there were no significant statistical differences between the two drugs in other outcomes. Conclusion This meta-analysis suggests that tolterodine is superior to α-adrenergic receptor blockers in improving physical pain symptoms after ureteral stent placement, while α-adrenergic receptor blockers are more effective than tolterodine in enhancing work performance. Additionally, the incidence of dry mouth is higher with the use of tolterodine compared to α-adrenergic receptor blockers. However, higher-quality randomized controlled trials are needed to further investigate this issue.

show abstract

Section: Study Selection Search Results and Characteristics Of The Tr...mentioning

confidence: 99%

Comparison of the efficacy and complications of tolterodine and α-adrenergic receptor blockers in improving ureteral stent-related symptoms: A systematic review and meta-analysis

Liu,

Mao

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Those sections mainly include. (9) • Urinary symptom index (11-56) scores • Pain symptom index (2-43) scores • General health (4-28) scores • Work performance index (5-25) scores • Sexual matters (1-12) scores • Additional problems (5-17) scores (9,10) USSQ is considered as the first validated tool to evaluate the stent related symptoms. It's a most reliable instrument that is expected to become a standard outcome measure to evaluate the impact.…”

Section: Introductionmentioning

confidence: 99%

Study on Evaluation of Medication Use Patterns in the Management of Ureteral Stent Discomfort

SHARABU¹,

MEKALA²,

SHAIK³

et al. 2022

YMER

View full text Add to dashboard Cite

Background: The insertion of double -j stents is considered as a routine and common Urological procedure. It can cause stent related discomfort, which affect nearly 80% of patients with indwelling ureteral symptoms, pharmacological management is one of the main trails that were done to reduce ureteral stent discomfort. This study aimed to evaluate the drug utilization patterns in management of ureteral stent discomfort. Methods: This prospective, observational study was conducted in the Department of Urology. 54 patients were enrolled into the study who underwent ureteral stent positioning, and evaluated the prescription patterns and by administration of validated USSQ for assessment of stent related symptoms. Results: 54 prescription patterns were evaluated and among them 39 are receiving Tamsulosin and 15 are receiving Tamsulosin + Tolterodine. During the follow up the USSQ scores were significantly low after the drug administration. The USSQ scores of Tamsulosin when compared with Tamsulosin in combination with tolterodine, there was significantly more improvement in the reduction of stent discomfort during the combination therapy. Conclusion: Alpha blockers (Tamsulosin), in patients with indwelling stents reduces the stent related symptoms. Combination of alpha blockers (Tamsulosin) and anticholinergics (Tolterodine) seems to have a better efficacy in improving the ureteral stent discomfort. KEY-WORDS: Ultrasonography, Ureteroscopy, Ureteroscopic lithotripsy, Ureteral stent symptom questionnaire (USSQ)

show abstract

Long-Term Outcomes of Two Ipsilateral vs Single Double-J Stent After Laser Endoureterotomy for Bilharzial Ureteral Strictures

Mohyelden

Hussein

Helaly

et al. 2021

Journal of Endourology

View full text Add to dashboard Cite

Impact of Tamsulosin, Tolterodine and drug-combination on the outcomes of lower urinary tract symptoms secondary to post-ureteroscopy ureteral stent: A prospective randomized controlled clinical study

Cited by 3 publications

References 13 publications

Comparison of the efficacy and complications of tolterodine and α-adrenergic receptor blockers in improving ureteral stent-related symptoms: A systematic review and meta-analysis

Comparison of the efficacy and complications of tolterodine and α-adrenergic receptor blockers in improving ureteral stent-related symptoms: A systematic review and meta-analysis

Study on Evaluation of Medication Use Patterns in the Management of Ureteral Stent Discomfort

Long-Term Outcomes of Two Ipsilateral vs Single Double-J Stent After Laser Endoureterotomy for Bilharzial Ureteral Strictures

Contact Info

Product

Resources

About